Peter Fasching

Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (42)

Background Wearables and smart devices could complement face-to-face prenatal care appointments by monitoring pregnant women's health, especially since pregnancy may be a vulnerable time when mental health issues and pregnancy-related anxiety may arise. Aim The aim of this study was to analyze the extent whether the willingness of women to use smart devices for pregnancy care monitoring differs between those with pregnancy-related anxiety and those without. Methods A survey was conducted to ascertain participant's general characteristics, attitudes toward smart devices, the willingness to use them, and the level of pregnancy-related anxiety (PRAQ-R2). Associations between the willingness and pregnancy-related anxiety parameters were analyzed. Results Completed questionnaires from 210 women were included in the analysis. A significant difference between women showing high and low levels of pregnancy-related anxiety was observed in terms of their willingness to use a smartwatch (median score 4.00; interquartile range (IQR) 4.00–5.00 vs. 4.00; IQR 3.00–4.00; P = .02), smart contraction counter (median score 4.00; IQR 3.00–5.00 vs. 3.00; IQR 3.00–4.00; P = .02), smart blood pressure monitor (median score 5.00; IQR 3.00–5.00 vs. 4.00; IQR 3.00–4.00; P = .003) or sleep tracker (median score 4.00; IQR 3.00–5.00 vs. 3.00; IQR 2.00–4.00; P = .007). Overall, anxious women showed significantly higher willingness to use smart devices in the context of prenatal care. Conclusions The data suggest that pregnant women are receptive to using smart devices to enhance their prenatal care, particularly those experiencing higher levels of anxiety. This study serves as an initial step in evaluating attitudes toward these devices. As a follow-up, it is recommended that acceptance and feasibility studies are conducted alongside the further development of existing and new pregnancy-specific wearables.

Year:

2026

IDFS by HER2 IHC score at definitive surgery (derived from samples used for eligibility and exploratory purposes). IDFS, invasive disease-free survival; IHC, immunohistochemistry; T-DM1, trastuzumab emtansine.

Year:

2025

Kaplan–Meier curves of OS in ( A ) main tumor groups ( n = 582)—MBOT, MOC, LGI, and UGI; ( B ) patients with MOC by FIGO stage ( n = 184); ( C ) patients with MOC by pattern of invasion in all stages ( n = 178); and ( D ) patients with stage I MOC ( n = 134), by pattern of invasion.

Year:

2025

HER2, PD-L1, and Five-Gene Signature Quartile Analysis. IDFS by HER2 gene expression quartile (A) in the trastuzumab arm; and (B) in the T-DM1 arm; (C) treatment effect on IDFS by HER2 gene expression quartile; (D) effect of HER2 gene expression quartile on IDFS; IDFS by PD-L1 gene expression quartile (E) in the trastuzumab arm; and (F) in the T-DM1 arm; (G) treatment effect on IDFS by PD-L1 gene expression quartile; (H) effect of PD-L1 gene expression quartile on IDFS; IDFS by five-gene signature (i.e., PD-L1/granzymeB/CD8/IFNγ/CXCL9) gene expression quartile (I) in the trastuzumab arm; and (J) in the T-DM1 arm; (K) treatment effect on IDFS by five-gene signature gene expression quartile; (L) effect of five-gene signature gene expression quartile expression on IDFS. Each expression quartile (quartile 2, quartile 3, and quartile 4) is compared to the lowest quartile (quartile 1). The analyses are unstratified and adjusted using a Cox regression model that includes percent tumor in marked area, clinical stage at presentation, hormone receptor status, type of preoperative HER2-directed therapy, and pathologic nodal status. HER2, human epidermal growth factor receptor 2; IDFS, invasive disease-free survival; IFNγ, interferon gamma; Q, quartile; T-DM1, trastuzumab emtansine.

Year:

2025

Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.

Year:

2025

Comparison of HER2 expression intensity in paired pre-NAT (i.e., before surgery) and post-NAT surgical samples. HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NAT, neoadjuvant therapy.

Year:

2025

Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis ( n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.

Year:

2025

Comparison of IDFS outcomes in the ITT population compared to the (A) RNA-evaluable population (REP) (including pre- and post-NAT surgical samples) and in patients with (B) pre-NAT REP samples (left) or post-NAT surgical REP samples (right). HER2, human epidermal growth factor receptor 2; IDFS, invasive disease-free survival; IHC, immunohistochemistry; ITT, intent-to-treat; NAT, neoadjuvant therapy; T-DM1, trastuzumab emtansine.

Year:

2025

Comparison of baseline patient and disease characteristics assessed at eligibility in the ITT population versus in those with mRNA data derived from pre-NAT or post-NAT surgical samples (RNA-evaluable population). Note: the pre-NAT and post-NAT samples are not paired.

Year:

2025

Comparison of pre-NAT and post-NAT surgical RNA-evaluable samples. (A) ERBB2 (i.e., HER2), CD274 (i.e., PD-L1), checkpoint inhibitor signature (i.e., PD-L1/PD-L2/IDO), CD8A (i.e., CD8), TEFF signature CD8/granzymeA/granzymeB/perforin/IFNγ), three-gene signature (i.e., PD-L1/IFNγ/CXCL9), five-gene signature (i.e., PD-L1/granzymeB/CD8/IFNγ/CXCL9), Th1 cytokine signature (i.e., CXCL9/CXCL10/CXCL11), and B cell gene expression. (B) Frequency of AIMS PAM50 subtypes overall and by hormone receptor status. (C) Frequency of AIMS PAM50 subtypes by level of HER2 protein expression assessed by IHC in pre- and post-NAT samples. (D) Frequency of AIMS PAM50 subtypes by level of HER2 gene expression in pre- and post-NAT samples. (E) Hallmark gene sets enriched for genes upregulated in post-NAT surgical versus pre-NAT samples (adjusted P

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (100)

Charlie Gourley

University of Edinburgh

UNITED KINGDOM
View details

Carsten Denkert

Philipps-Universität Marburg

GERMANY
View details

Sue K. Park

Professor

Seoul National University College of Medicine

SOUTH KOREA
View details

Eric Hahnen

-

GERMANY
View details

Kathryn Terry

Co-Scientific Director

Boston Children's Hospital

UNITED STATES
View details

Elizabeth Christie

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Timothy Budden

Lecturer

University of Liverpool

UNITED KINGDOM
View details

Beth Karlan

Vice Chair

University of California, Los Angeles

UNITED STATES
View details

Anna Jakubowska

Head

Pomeranian Medical University

POLAND
View details

Lynne Wilkens

Professor

University of Hawaii at Manoa

UNITED STATES
View details

Anthony Swerdlow

Professor of Epidemiology

Institute of Cancer Research Sutton

UNITED KINGDOM
View details

Patrick Neven

University Hospitals Leuven

BELGIUM
View details

Sherene Loi

University of Melbourne

AUSTRALIA
View details

Matthew Wakefield

University of Melbourne

AUSTRALIA
View details

Martin Widschwendter

Professor; Director

University of Innsbruck

AUSTRIA
View details

P. M. Webb

Group Leader

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Martin Köbel

Associate Professor

University of Calgary

CANADA
View details

Estrid V. Hoegdall

University of Copenhagen

DENMARK
View details

Paul Timpson

Co-Director ACRF (INCITe) Centre

Garvan Institute of Medical Research

AUSTRALIA
View details

James D Brenton

University of Cambridge

UNITED KINGDOM
View details

Jae-Weon Kim

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Peter Sinn

Head, Division of Gynaecopathology

University Hospital

GERMANY
View details

Zbigniew Nowecki

Head od Department

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND
View details

Charles Edward Geyer Jr

Professor of Medicine in Division of Hematology/Medical Oncology

University of Pittsburgh

UNITED STATES
View details

Cezary Cybulski

Pomeranian Medical University

POLAND
View details

Lyndal Anderson

University of Western Sydney

AUSTRALIA
View details

Sabine Kasimir-Bauer

University Hospital Essen

GERMANY
View details

Claus Høgdall

Professor in Clinical Gynecologic Oncology

University of Copenhagen

DENMARK
View details

Hanna Huebner

University Hospital Erlangen

GERMANY
View details

Lindsay J Collin

Assistant Professor

Emory University

UNITED STATES
View details

Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christine Solbach

Goethe University Frankfurt

GERMANY
View details

Judith Balmaña

Head

Hospital Universitari Vall d'Hebron

SPAIN
View details

Heike Leutheuser

Professor of Ambient Assisted Living & Medical Assistance Systems at University of Bayreuth

University of Bayreuth

GERMANY
View details

Anthony Gill

University of Sydney

AUSTRALIA
View details

Linda Cook

Professor

University of Colorado Cancer Center

UNITED STATES
View details

Paul James

Head of Adult Genetics

The Royal Melbourne Hospital Royal Park Campus

AUSTRALIA
View details

Parham Minoo

Associate Clinical Professor of Pathology

University of Calgary

CANADA
View details

Angela Brooks-Wilson

Simon Fraser University

CANADA
View details

Tomasz Kluz

Professor

Rzeszów University

POLAND
View details

Joellen Schilkdraut

Professor

Emory University

UNITED STATES
View details

Mark Basik

McGill University

CANADA
View details

Francois-Clement Bidard

Professor of Medical Oncology

Institut Curie

FRANCE
View details

Michael Anglesio

Associate Professor

The University of British Columbia

CANADA
View details

Ramona Erber

W2-Professorin, Oberärztin

University of Regensburg

GERMANY
View details

Nicholas Hawkins

Emeritus Professor

UNSW Sydney

AUSTRALIA
View details

Usha Menon

Professor of Gynaecological Oncology

University College London

UNITED KINGDOM
View details

Terence Williams

City Of Hope National Medical Center

UNITED STATES
View details

Nadia Harbeck

-

GERMANY
View details

Hope Rugo

Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology

City Of Hope National Medical Center

UNITED STATES
View details

Judith Lea Lindner

-

GERMANY
View details

Kelly K Hunt

Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Dennis J. Slamon

University of California, Los Angeles

UNITED STATES
View details

Tanja Fehm

Professor

University Hospital Düsseldorf

GERMANY
View details

Peter Schmid

Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine

Barts Cancer Institute

UNITED KINGDOM
View details

Sandra Orsulic

Professor

University of California, Los Angeles

UNITED STATES
View details

Cheng-Han Lee

Associate Professor

University of Alberta

CANADA
View details

Ian Campbell

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Jae-Hoon Kim

Yonsei University College of Medicine

SOUTH KOREA
View details

Anna H. Wu

Professor

University of Southern California

UNITED STATES
View details

C Blake Gilks

-

CANADA
View details

Thomas Karn

Goethe University Frankfurt

GERMANY
View details

Francesmary Modugno

University of Pittsburgh

UNITED STATES
View details

Swati Kulkarni

Professor of Surgery

Northwestern University

UNITED STATES
View details

Alexander Hein

-

GERMANY
View details

Kylie-Ann Mallitt

Senior Lecturer in Biostatistics

University of Sydney

AUSTRALIA
View details

Dale Garsed

University of Melbourne

AUSTRALIA
View details

Philip Crowe

Professor Surgery

University of New South Wales

AUSTRALIA
View details

Renée Fortner

Head of Division

Deutsches Krebsforschungszentrum

GERMANY
View details

K Sundfeldt

Professor/Consultant

University of Gothenburg, Sahlgrenska Academy

SWEDEN
View details

Tomasz Huzarski

Pomeranian Medical University

POLAND
View details

Byoung-Gie Kim

Sungkyunkwan University School of Medicine

SOUTH KOREA
View details

Guillermo Villacampa Javierre

Biostatistician

Vall d´Hebron Institute of Oncology

SPAIN
View details

Banu K. Arun

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Dane Cheasley

Senior Research Fellow

University in Western Australia

AUSTRALIA
View details

Gregg Nelson

Gynecologic Oncologist

University of Calgary

CANADA
View details

Sara Hurvitz

Professor, Division Head

Washington University School of Medicine

UNITED STATES
View details

Changxian Shen

City of Hope

UNITED STATES
View details

Jennifer Anne Doherty

Professor

University of Utah

UNITED STATES
View details

Peter Lucas

Professor and Vice Chair of Research

Mayo Clinic

UNITED STATES
View details

Paul Pharoah

Professor of Cancer Epidemiology

Cedars-Sinai Medical Center

UNITED STATES
View details

Brenda Y Hernandez

University of Hawaii

UNITED STATES
View details

Michael Edwin Jones

Senior Staff Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Kylie L Gorringe

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Jan Lubiński

Head of Dept

Pomeranian Medical University

POLAND
View details

Mona El-Bahrawy

Imperial College London

UNITED KINGDOM
View details

Aleksandra Gentry-Maharaj

University College London

UNITED KINGDOM
View details

Miguel Martin

Universidad Complutense de Madrid

SPAIN
View details

Violeta Serra

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

Manali Bhave

Assistant Professor

Winship Cancer Institute of Emory University

UNITED STATES
View details

David G. Huntsman

The University of British Columbia

CANADA
View details

Janusz Menkiszak

Head of the University Clinic

Pomeranian Medical University

POLAND
View details

Eva M. Ciruelos-Gil

Universidad Complutense de Madrid

SPAIN
View details

Clare Scott

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA
View details

Susan Ramus

Professor of Molecular Oncology

University of New South Wales

AUSTRALIA
View details

Paul Jank

Head of Translational Research Laboratory

-

GERMANY
View details

Paul Cohen

University of Western Australia

AUSTRALIA
View details

Aline Talhouk

Assistant Professor

The University of British Columbia

CANADA
View details

David Lawson Morris

Professor of Surgery

University of New South Wales

AUSTRALIA
View details